Yujiro S. Hata - 01 Feb 2024 Form 4 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Signature
/s/ Jason Throne, as Attorney-in-Fact for Yujiro Hata
Issuer symbol
IDYA
Transactions as of
01 Feb 2024
Net transactions value
-$25,553
Form type
4
Filing time
05 Feb 2024, 18:05:39 UTC
Previous filing
17 Jan 2024
Next filing
12 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDYA Common Stock Options Exercise $2,707 +628 +0.09% $4.31 678,515 01 Feb 2024 Direct
transaction IDYA Common Stock Sale $28,080 -624 -0.09% $45.00 677,891 01 Feb 2024 Direct F1
transaction IDYA Common Stock Sale $180 -4 -0% $45.01 677,887 01 Feb 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDYA Stock Option (right to buy) Options Exercise $0 -628 -0.19% $0.000000 323,826 01 Feb 2024 Common Stock 628 $4.31 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 11, 2023.
F2 The shares subject to the option are fully vested and exercisable.